魚躍醫療(002223.SZ)：擬受讓浙江凱立特醫療器械的50.993%股權
格隆匯 5 月 10日丨魚躍醫療(002223.SZ)公佈，公司擬受讓浙江凱立特醫療器械有限公司(“凱立特”、“標的公司”)股東LenoMed Venture Limited (“LenoMed Venture ”)、凱聯醫療科技(上海)有限公司(“凱聯醫療”)、Ocean Anchor Investments Limited (“Ocean Anchor Investments”)、天津天士力健康產業投資合夥企業(有限合夥)(“天士力”)、通化東寶藥業股份有限公司(“通化東寶”)、蘇州工業園區新建元二期創業投資企業(有限合夥)(“蘇州新建元”)、Ascensia Diabetes Care Holdings AG (“Ascensia DiabetesCare”)共計7方(“轉讓方”)合計持有的凱立特的50.993%股權，同時授權管理層與交易對方簽署相應的《股權轉讓協議》。
此次交易的交易對價系按照凱立特整體股權估值8億元計算並經各方協商一致確定，各轉讓方將其持有的合計標的公司50.993%的股權(對應公司的人民幣2425.55826萬元註冊資本)轉讓給受讓方，該等擬轉讓股權的股權轉讓價值應為人民幣40794.36914萬元。因截至目前，Ascensia Diabetes Care尚未履行前輪融資協議項下4200萬的出資義務，故此次交易魚躍醫療需向交易對方支付36594.36914萬元(已扣除Ascensia Diabetes Care尚未履行的前述4200萬出資義務)，並需承繼Ascensia Diabetes Care尚未履行之前輪融資協議項下的4200萬出資義務。
凱立特成立於2010年，致力於研發、生產、銷售以高端生物傳感器為核心技術的醫用便攜式監測系統，包括動態血糖監測(CGM)、血氣及電解質、以及其他POCT即時檢驗產品，並通過提供全面、有效和經濟的糖尿病管理方案，成為業界領先的技術創新者和領導者。
凱立特創始人張亞南是美國Kansas大學生物分析化學博士，藥物分析化學及生物傳感器博士後，曾先後擔任美國Oread Inc.藥物分析科學家，美國美敦力公司(Medtronic, Inc.)首席傳感器科學家，美國Microchip Technology Inc. (MCHP)公司研發總監。張亞南先生主導並參與研發了全球首例人工胰臟的葡萄糖傳感器，以及第一個動態血糖產品CGMSGold，是美國長期動態傳感器及植入式陣列芯片的主要研究者。
凱立特動態血糖監測產品在2016年和2021年已經分別獲得歐盟CE認證和中國國家食品藥品監督管理總局醫療器械註冊證。
此次收購完成後，標的公司的連續血糖監測業務可依託上市公司規模化、智能化、精益化的生產能力，共享上市公司BGM銷售資源、軟件開發資源及用户運營能力，實現研發、生產、銷售及用户服務等多方面的協同，實現雙方強強聯合，完成魚躍醫療在糖尿病賽道的完整業務佈局，保障上市公司整體業績的長期持續穩定增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
